Cimetidine, when intended for the short-term symptomatic relief of heartburn, dyspepsia and
hyperacidity, subject to—
(a)
a maximum dose of 200 milligrams;
(b)
a maximum daily dose (per 24 hours) of 800 milligrams;
(c)
a maximum treatment period of 2 weeks. (S3)
Clidinium bromide.
Codeine (methylmorphine); preparations and mixtures when compounded with one or more
therapeutically active substances and containing 20 milligrams or less of codeine (calculated as base)
per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of codeine
(calculated as base) per 5 millilitre dosage unit. (S6)
Colchicine, in cases of emergency. (S3)
Contrast media.
Cydandelate.
Cydopentolate, except ophthalmic preparations thereof. (S3)
Desloratidine.
Dextromethorphan.
Diclofenac, when intended for the emergency treatment of acute gout attacks, and when intended for
the treatment of post traumatic conditions such as pain, swelling and inflammation, for maximum period
of 5 days. (S1, S3)
Dicyclomine.
Difenoxin (or diphenoxylic acid); mixtures containing, per dosage unit, 0,5 milligrams or less of difenoxin,
calculated as the base, and a quantity of atropine sulphate equal to at least 5,0 per cent of such quantity
of difenoxin, calculated as the base, as is present in the mixture. (S6)
Dihydrocodeine; preparations and mixtures when compounded with one or more therapeutically active
substances and containing 20 milligrams or less of dihydrocodeine (calculated as base) per dosage unit
and liquid oral preparations and mixtures containing 20 milligrams or less of dihydrocodeine (calculated
as base) per 5 millilitre dosage unit. (S6)
Diphenoxylate; preparations containing not more than 2,5 milligrams of diphenoxylate, calculated as the
base, and not less than 25 micrograms of atropine sulphate per dosage unit. (S6)
{D-norpseudoephedrine – see cathine.}
Domperidone.
Emedastine.
Emepronium.
Ephedra alkaloids (natural or synthetic), other than ephedrine preparations and mixtures intended for
application to the skin, eyes, ears and nares containing 1,0 per cent or less of ephedra alkaloids, and
other preparations and mixtures containing not more than 30 milligrams of ephedrine or ephedra
alkaloids per dose. (S1, S5)
Ephedrine contained in products registered in terms of the Act, except preparations and mixtures
intended for application to the skin, eyes, ears and nares containing 1,0 per cent or less of ephedrine,
and other oral preparations and mixtures containing not more than 30 milligrams of ephedrine per dose.
(S1, S5)
Ergot alkaloids (natural or synthetic), when intended for the treatment of migraine. (S4)
Ethylmorphine; preparations and mixtures when compounded with one or more therapeutically active
substances and containing 20 milligrams or less of ethylmorphine (calculated as base) per dosage unit
and liquid oral preparations and mixtures containing 20 milligrams or less of ethylmorphine (calculated
as base) per 5 millilitre dosage unit. (S6)
Etilefrine.
Exalamide.
Famotidine, when intended for the short-term symptomatic relief of heartburn caused by excess acid,
subject to—
(a)
a maximum dose of 10 milligrams;
(b)
a maximum daily dose (per 24 hours) of 20 milligrams;
(c)
a maximum treatment period of 2 weeks. (S4)
Fedrilate.
Fenoprofen, when intended for the emergency treatment of acute gout attacks and when intended for
the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum
period of 5 days. (S3)
Fenoterol, except when contained in respirator solutions (S3) and except when intended for injection or
for the prevention or delay of labour. (S4)
Flavoxate.
Flunisolide, when intended for nasal administration, other than by aerosol in a strength not exceeding
0,025 per cent (w/v), indicated for treatment of the symptoms of seasonal allergic rhinitis (hay fever) in
adults and children over 12, subject to—
(a)
a maximum dose of 50 micrograms per nostril and a maximum daily dose of 100
micrograms per nostril in the case of adults and children over the age of 16 years;
(b)
a maximum dose of 25 micrograms per nostril and a maximum daily dose of 75
micrograms per nostril in the case of children 12 to 16 years of age; and